1 ratings / 4 average

Orthopedic Surgery

Turun S, Banghua L, Yuan Y et al.  Thromb Res 2011;127:525–34.

The aim of the present study was to compare rivaroxaban with enoxaparin for venous thromboembolism prevention after knee joint or hip joint replacement. In all, eight randomized controlled studies (n=15246) were assessed. The results suggest that rivaroxaban is superior to enoxaparin. Therapy duration of >30 days is recommended.


Venous thromboembolism (VTE) and its two major clinical manifestations of deep vein thrombosis (DVT) and pulmonary embolism (PE) are major complications of orthopedic surgery for total hip arthroplasty (THA) or total knee arthroplasty (TKA). Rivaroxaban is a novel and reversible Factor Xa inhibitor with a promising antithrombosis effect. Its advantages over heparin and warfarin are its oral administration, short half-life, peak time, and rapid onset of antithrombotic effect.

Return to top